Jump to content

Jeffrey Hill

Add links
From Wikipedia, the free encyclopedia
(Redirected from Draft:Jeffrey Hill)
For "Jeffrey Hill" near Longridge, England, see Longridge Fell.

Jeffrey Hill is a British scientist who is currently Vice President and Head of Biology, Center for Translational Research at the Shenzhen Bay Laboratory.[1] He was formerly a Professor of Drug Discovery and director of the Sussex Drug Discovery Centre at the University of Sussex.[2] He contributed to the discovery of Singapore's first publicly funded drug candidates during his time at the Agency for Science, Technology and Research (A*STAR).[3][4][5]

Education and early career

[edit]

Hill worked as a Medical Laboratory Scientific Officer at Nevill Hall Hospital, Abergavenny, Wales before completing his university education at Cardiff University where his doctoral research focused on aspartic proteinases.[6] He developed an interest in drug discovery for tropical diseases and after completing a WHO funded postdoctoral project on plasmodial proteinases in 1997, he became a Group Leader at Mahidol University.[7] His research group focused on the characterisation of proteinases from a number of viruses including dengue.[8]

Career

[edit]

In 1998, Hill returned to the United Kingdom and joined GlaxoSmithKline (GSK). He worked at the company for 8 years in both the Discovery Research and Genetics Research divisions where he was involved in target validation, assay development and biomarker discovery.[9] He received the Scientific Impact Award at GSK for cloning a novel human GPCR and an Exceptional Science Award for the identification of novel biomarkers.[10]

Hill left GSK in 2006 to join A*STAR's Bioinformatics Institute where he worked on gastric cancer biomarkers before helping Sir David Lane and Nobel Laureate Sydney Brenner establish the Experimental Therapeutics Centre (ETC), an A*STAR research institute focused on the discovery of drug candidates in 2007.[11][12] Working with Alex Matter, Hill led the institute in putting three novel molecular entities into the clinic: a vaccine based on virus like particle technology, a MNK kinase inhibitor for blood cancers and a PORCN inhibitor for solid tumours.[13][14][15] Other molecules discovered by his group have been used as chemical probes by other researchers to study autism and neurodegenerative diseases.[16][17] His work at ETC led him to receive the Ministry of Trade and Industry's Borderless Award and substantial research funding (including S$10 million for a cancer companion diagnostics program).[1]

Hill returned to the United Kingdom in 2019 to take up a position at the University of Sussex.[18] While he was a Professor in the School of Life Sciences and director of the university's drug discovery department he led a number of ion channel projects and investigated EBV driven cancers, for which he received funding from the Wellcome Trust and Cancer Research UK.[19]

In 2021, Hill moved to China to become Vice President at the Shenzhen Bay Laboratory. He is based at the Center for Translational Research where is Head of Biology and pursues targets in infectious diseases and oncology.[1][20][21]

References

[edit]
  1. ^ a b c "Jeffrey Hill". www.szbl.ac.cn. Retrieved 2021-12-06.
  2. ^ "Sussex Drug Discovery Centre appoints Professor Jeffrey Hill as new Director". www.myscience.uk. 2019-06-28. Retrieved 2021-12-06.
  3. ^ "Professor Jeffrey Hill, Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex". Events - University of Kent. Retrieved 2021-12-06.
  4. ^ Madan, Babita; Ke, Zhiyuan; Harmston, Nathan; Petretto, Enrico; Hill, Jeffrey; Keller, Thomas H.; Lee, May Ann; Matter, Alex; Virshup, David M. (2016-04-01). "Abstract B13: ETC-159 is a novel PORCN inhibitor effective for treatment of Wnt-addicted genetically defined cancers". Molecular Cancer Research. 14 (4 Supplement): B13. doi:10.1158/1557-3125.DEVBIOLCA15-B13. ISSN 1541-7786.
  5. ^ Yang, Haiyan; Chennamaneni, Lohitha Rao; Ho, Melvyn Wai Tuck; Ang, Shi Hua; Tan, Eldwin Sum Wai; Jeyaraj, Duraiswamy Athisayamani; Yeap, Yoon Sheng; Liu, Boping; Ong, Esther Hq; Joy, Joma Kanikadu; Wee, John Liang Kuan (2018-05-24). "Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia". Journal of Medicinal Chemistry. 61 (10): 4348–4369. doi:10.1021/acs.jmedchem.7b01714. ISSN 1520-4804. PMID 29683667.
  6. ^ Hill, Jeffrey; Tyas, Lorraine; Phylip, Lowri H.; Kay, John; Dunn, Ben M.; Berry, Colin (1994-09-26). "High level expression and characterisation of Plasmepsin II, an aspartic proteinase fromPlasmodium falciparum". FEBS Letters. 352 (2): 155–158. doi:10.1016/0014-5793(94)00940-6. ISSN 0014-5793. PMID 7925966. S2CID 24113131.
  7. ^ Tatnell, Peter J; Powell, David J; Hill, Jeffrey; Smith, Trudi S; Tew, David G; Kay, John (1998-12-11). "Napsins: new human aspartic proteinases: Distinction between two closely related genes". FEBS Letters. 441 (1): 43–48. doi:10.1016/S0014-5793(98)01522-1. ISSN 0014-5793. PMID 9877162. S2CID 27656626.
  8. ^ Sciences, School of Life. "Sussex Drug Discovery Centre appoints Professor Jeffrey Hill as new Director". The University of Sussex. Retrieved 2021-12-06.
  9. ^ Hill, Jeffrey; Duckworth, Malcolm; Murdock, Paul; Rennie, Gillian; Sabido-David, Cibele; Ames, Robert S.; Szekeres, Philip; Wilson, Shelagh; Bergsma, Derk J.; Gloger, Israel S.; Levy, Dana S. (2001-01-01). "Molecular Cloning and Functional Characterization of MCH2, a Novel Human MCH Receptor *". Journal of Biological Chemistry. 276 (23): 20125–20129. doi:10.1074/jbc.M102068200. ISSN 0021-9258. PMID 11274220.
  10. ^ Robbins, M. J.; Michalovich, D.; Hill, J.; Calver, A. R.; Medhurst, A. D.; Gloger, I.; Sims, M.; Middlemiss, D. N.; Pangalos, M. N. (2000-07-01). "Molecular Cloning and Characterization of Two Novel Retinoic Acid-Inducible Orphan G-Protein-Coupled Receptors (GPRC5B and GPRC5C)". Genomics. 67 (1): 8–18. doi:10.1006/geno.2000.6226. ISSN 0888-7543. PMID 10945465.
  11. ^ Lee, Bernett T.K.; Song, Chun Meng; Yeo, Boon Huat; Chung, Cheuk Wang; Chan, Ying Leong; Lim, Teng Ting; Chua, Yen Bing; Loh, Marie C.S.; Ang, Boon Keong; Vijayakumar, Praveen; Hill, Jeffrey (2006-01-01). "Gastric Cancer (Biomarkers) Knowledgebase (GCBKB): A Curated and Fully Integrated Knowledgebase of Putative Biomarkers Related to Gastric Cancer". Biomarker Insights. 1: 117727190600100005. doi:10.1177/117727190600100005. ISSN 1177-2719. S2CID 207954308.
  12. ^ "Speech by Mr Lim Chuan Poh, Chairman of A*STAR". 00. A*STAR HQ Corporate Website. Retrieved 2021-12-06.
  13. ^ Madan, B.; Ke, Z.; Harmston, N.; Ho, S. Y.; Frois, A. O.; Hill, J; Jeyaraj, D. A.; Pendharkar, V.; Ghosh, K.; Virshup, I. H.; Manoharan, V. (April 2016). "Wnt addiction of genetically defined cancers reversed by PORCN inhibition". Oncogene. 35 (17): 2197–2207. doi:10.1038/onc.2015.280. ISSN 1476-5594. PMC 4650263. PMID 26257057.
  14. ^ Lim, Sharon; Saw, Tzuen Yih; Zhang, Min; Janes, Matthew R.; Nacro, Kassoum; Hill, Jeffrey; Lim, An Qi; Chang, Chia-Tien; Fruman, David A.; Rizzieri, David A.; Tan, Soo Yong (2013-06-18). "Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function". Proceedings of the National Academy of Sciences. 110 (25): E2298–E2307. Bibcode:2013PNAS..110E2298L. doi:10.1073/pnas.1301838110. ISSN 0027-8424. PMC 3690864. PMID 23737503.
  15. ^ Teneggi, V.; Ng, M.; Tan, D. S.; Subbiah, V.; Weekes, C.; Diermayr, V.; Ethirajulu, K.; Yeo, P.; Chen, D.; Gan, S.; Hill, J. (2016-12-01). "152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours". Annals of Oncology. 27: ix47. doi:10.1016/S0923-7534(21)00310-0. ISSN 0923-7534.
  16. ^ Hörnberg, Hanna; Pérez-Garci, Enrique; Schreiner, Dietmar; Hatstatt-Burklé, Laetitia; Magara, Fulvio; Baudouin, Stephane; Matter, Alex; Nacro, Kassoum; Pecho-Vrieseling, Eline; Scheiffele, Peter (August 2020). "Rescue of oxytocin response and social behaviour in a mouse model of autism". Nature. 584 (7820): 252–256. Bibcode:2020Natur.584..252H. doi:10.1038/s41586-020-2563-7. ISSN 1476-4687. PMC 7116741. PMID 32760004.
  17. ^ Escande-Beillard, Nathalie; Loh, Abigail; Saleem, Sahar N.; Kanata, Kohei; Hashimoto, Yui; Altunoglu, Umut; Metoska, Artina; Grandjean, Joanes; Ng, Fui Mee; Pomp, Oz; Baburajendran, Nithya (2020-07-08). "Loss of PYCR2 Causes Neurodegeneration by Increasing Cerebral Glycine Levels via SHMT2". Neuron. 107 (1): 82–94.e6. doi:10.1016/j.neuron.2020.03.028. ISSN 0896-6273. PMID 32330411. S2CID 216095942.
  18. ^ Sciences, School of Life. "Sussex Drug Discovery Centre appoints Professor Jeffrey Hill as new Director". The University of Sussex. Retrieved 2021-12-07.
  19. ^ "Jeffrey Hill Sussex Research Grants". profiles.sussex.ac.uk. Retrieved 2021-12-06.
  20. ^ Li, Yan; Zhang, Zhenzhen; Phoo, Wint Wint; Loh, Ying Ru; Li, Rong; Yang, Hai Yan; Jansson, Anna E.; Hill, Jeffrey; Keller, Thomas H.; Nacro, Kassoum; Luo, Dahai (2018-04-03). "Structural Insights into the Inhibition of Zika Virus NS2B-NS3 Protease by a Small-Molecule Inhibitor". Structure. 26 (4): 555–564.e3. doi:10.1016/j.str.2018.02.005. ISSN 0969-2126. PMID 29526431.
  21. ^ Ke, Xin-Yu; Chen, Ye; Tham, Valarie Yu-Yan; Lin, Ruby Yu-Tong; Dakle, Pushkar; Nacro, Kassoum; Puhaindran, Mark Edward; Hill, Jeffrey; Pang, Angela; Lee, Victor Kwanmin; Ding, Ling-Wen (2021-03-01). "MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma". Oncogene. 40 (10): 1851–1867. doi:10.1038/s41388-021-01661-4. ISSN 1476-5594. PMC 7946644. PMID 33564073.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Jeffrey_Hill&oldid=1181327404"